Joe Rogan TRT: The Ethics of Celebrity Prescription Drug Disclosure

What Joe Rogan Has Actually Said About TRT

Joe Rogan has discussed testosterone replacement therapy in detail across multiple episodes of The Joe Rogan Experience, the world's most-downloaded podcast. He describes TRT as a routine part of his health regimen, often alongside NAD+ infusions, the peptide BPC-157, and, in earlier episodes, human growth hormone. His framing is consistently personal: he explains what his own labs showed, how he feels on therapy, and who prescribes for him. No clinical trial data. No mention of contraindications.

That framing matters enormously when your audience numbers in the tens of millions per episode.

The Specific Therapies Rogan Has Named

Testosterone Replacement Therapy. Rogan has stated he uses injectable testosterone and has described the subjective benefits: higher energy, faster recovery, and improved mood. These reported effects are consistent with the peer-reviewed literature. A 2010 meta-analysis in JAMA Internal Medicine covering 51 randomized controlled trials found testosterone therapy significantly improved lean body mass and reduced fat mass in men with low testosterone, though effects on sexual function and quality of life were more variable [1].

NAD+ Infusions. Rogan has mentioned intravenous nicotinamide adenine dinucleotide (NAD+) infusions for cognitive clarity and recovery. The clinical evidence here is thinner. A 2023 randomized trial published in Nature Aging (N=30) found oral NMN supplementation raised blood NAD+ levels in healthy older adults but did not demonstrate clear functional benefits over placebo at 60 days [2]. IV NAD+ specifically has very limited controlled human trial data.

BPC-157. Body Protection Compound-157 is a synthetic peptide derived from a gastric protein. Rogan has referenced it for injury recovery. Current evidence is largely preclinical. A 2018 review in Current Pharmaceutical Design summarized animal data showing accelerated tendon and ligament healing, but no large human RCTs exist as of 2025 [3]. The FDA has not approved BPC-157 for any indication [4].

HGH. In earlier episodes, Rogan mentioned using human growth hormone. HGH is FDA-approved only for specific diagnosed deficiencies. Off-label use in otherwise healthy adults carries risks including glucose intolerance and potential carcinogenesis with prolonged exposure, as noted in FDA prescribing guidance [5].

The Clinical Case for TRT When It Is Indicated

TRT is not a wellness supplement. It is a hormone replacement therapy approved for a specific medical condition: hypogonadism.

Who Actually Qualifies

The Endocrine Society 2018 Clinical Practice Guideline defines male hypogonadism as a serum total testosterone below 300 ng/dL on two separate morning measurements, combined with consistent symptoms such as reduced libido, erectile dysfunction, fatigue, or loss of muscle mass [6]. The guideline states directly: "We recommend against starting testosterone therapy in patients who have normal testosterone levels."

That threshold matters. A 2020 study in JAMA Network Open (N=4,986) found that among men who received a new testosterone prescription, 25.5% had no documented serum testosterone test in the six months prior [7]. Celebrity discourse almost certainly contributes to that prescribing pattern.

What the Evidence Shows for Hypogonadal Men

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials involving 788 men aged 65 and older with low testosterone, provided the most rigorous evidence to date. Published across NEJM and affiliated journals between 2016 and 2018, the trials found testosterone gel significantly improved sexual function, physical function, and bone density compared with placebo [8]. Mood and depressive symptoms also improved modestly. The trials did not find significant cardiovascular harm at one year, though longer-term cardiovascular data remain an active area of research.

Testosterone therapy does carry real risks. Polycythemia (elevated hematocrit) occurs in roughly 5.8% of treated men per a Cochrane systematic review [9]. Testicular atrophy and impaired spermatogenesis are predictable effects of exogenous testosterone suppressing the hypothalamic-pituitary-gonadal axis [10]. These are not abstractions. They require monitoring.

The Ethics of Celebrity Rx Disclosure

This is the section most telehealth articles skip. They should not.

The Autonomy Argument

One reasonable position holds that Rogan is exercising personal autonomy, which he has every right to do, and that disclosing his own medical choices simply provides information. Adults can evaluate that information. This view has merit. Concealing one's own medical practices is not required, and transparency from public figures has sometimes accelerated legitimate awareness of underdiagnosed conditions.

The Influence Problem

The counterargument is about asymmetric influence. Rogan's audience does not hear his disclosure the way a peer would hear a friend mention a prescription. His reach, his authority in certain subcultures, and the parasocial intimacy of long-form podcasting create conditions where personal anecdote becomes de facto medical advice. Research on parasocial relationships and health behavior has documented this dynamic. A 2022 study in Health Communication found that parasocial interactions with media personalities predicted health-related behavioral intentions more strongly than general media exposure alone [11].

When a listener hears Rogan describe TRT as the reason for his energy and physique, the listener does not hear the prior lab work, the physician supervision, or the monitoring protocol. They hear the outcome and want it.

The Missing Informed Consent Layer

Standard informed consent in clinical medicine requires a patient to understand the risks, benefits, alternatives, and uncertainties of a therapy before agreeing to it. Celebrity disclosure provides only the benefit narrative. Rogan has not, to public knowledge, spent comparable airtime describing hematocrit monitoring, injection-site complications, fertility suppression, or the contraindications in men with polycythemia vera, untreated sleep apnea, or certain prostate conditions. The FDA's prescribing information for testosterone products lists these contraindications explicitly [5].

The HealthRX clinical team developed the following intake framework for use when a patient presents citing a celebrity or podcast as their reason for requesting TRT:

The Celebrity-Prompted TRT Request: A Five-Point Clinical Intake Framework

1. Document the patient's chief symptom burden using a validated instrument (the ADAM questionnaire or AMS scale) before discussing labs.
2. Order two fasting morning total testosterone measurements (drawn before 10 AM) at least one week apart, along with LH, FSH, prolactin, CBC, and PSA.
3. Explicitly ask whether the patient has encountered celebrity or social media content about TRT. Note it in the chart. This helps separate symptom-driven requests from appearance-driven ones.
4. If testosterone is <300 ng/dL with consistent symptoms, discuss therapy including the monitoring schedule (hematocrit at 3 months, then annually; PSA at 3 and 12 months; lipids annually).
5. If testosterone is >300 ng/dL, counsel the patient that their levels are within reference range and explore other causes for their symptoms before initiating therapy.

Testosterone Prescribing Trends and the Podcast Effect

Testosterone prescribing in the United States rose roughly 3-fold between 2001 and 2011, far outpacing any change in the prevalence of diagnosed hypogonadism, according to a 2013 analysis published in JAMA Internal Medicine [12]. The authors flagged marketing as a primary driver. By the mid-2010s, direct-to-consumer advertising and, later, podcast culture began carrying that marketing function.

A 2016 study in JAMA found that only 74.7% of men who received a new testosterone prescription had a testosterone level measured in the prior year, and only 53% had a measurement indicating low testosterone [13]. This was before the current generation of telehealth testosterone clinics, and before podcasts had reached their current scale of influence.

The numbers suggest a prescribing environment already prone to indication drift. High-profile, repeated, enthusiastic personal endorsements from trusted cultural figures add pressure to that environment.

What Rogan Gets Right (And Where the Picture Is Incomplete)

Fairness requires acknowledging what his disclosure does well.

Rogan consistently states he uses a physician. He has named Dr. Mark Gordon and others over the years. He discusses testing. He talks about monitoring. For a percentage of listeners, that framework, seeing a doctor, getting labs, having supervision, is genuinely educational compared with the alternative of black-market testosterone purchased without any medical oversight.

A 2021 survey in Translational Andrology and Urology estimated that a meaningful subset of men who use anabolic steroids or testosterone outside of medical supervision do so without any baseline health screening [14]. To whatever extent Rogan's model of physician-supervised, lab-monitored TRT reaches that population and redirects them toward legitimate care, the outcome may be net positive.

The gap remains the incomplete picture. His enthusiastic endorsement of BPC-157 and NAD+ infusions outpaces the available human evidence for those compounds significantly. Listeners do not always have the background to distinguish FDA-approved testosterone therapy, with decades of RCT data behind it, from a synthetic peptide with only rat studies.

NAD+ and Peptides: Separating Signal from Noise

NAD+ Infusions

Nicotinamide adenine dinucleotide declines with age, and animal studies have shown that restoring NAD+ precursors extends healthspan in rodents [15]. This generated enormous excitement. Human data, by contrast, remain early. The 2023 Nature Aging NMN trial mentioned above showed measurable increases in blood NAD+ levels in older adults, but no significant improvement on functional outcomes versus placebo [2]. IV infusions deliver NAD+ more directly than oral supplements and may produce transient symptom effects, but controlled human data on IV NAD+ specifically are lacking as of this writing. The FDA has not approved any NAD+ formulation as a drug for aging or cognitive enhancement [4].

BPC-157 Status

BPC-157 is not FDA-approved, not available as a licensed pharmaceutical, and is typically compounded. The FDA issued a statement in 2022 restricting certain compounded peptides, noting safety concerns related to lack of clinical data [4]. Its legal status in the United States for human use remains complicated. Patients who request it based on podcast content deserve a straightforward explanation of where the evidence actually stands.

What Clinicians Should Do With Celebrity-Influenced Patients

Dismissing a patient who arrives citing Joe Rogan is the wrong move clinically and relationally. That patient is engaged with their health. They have done some form of research. The job is to redirect that engagement toward evidence.

A brief, non-judgmental response might look like: "I hear that, and TRT is a real, effective therapy for the right person. Let's find out if that's you." Then follow the five-point framework above.

The Endocrine Society guideline's diagnostic standard, two morning testosterone measurements below 300 ng/dL with consistent symptoms, exists precisely to protect patients from unnecessary therapy [6]. A 2019 systematic review in Annals of Internal Medicine covering 156 randomized trials of testosterone therapy found that cardiovascular event risk, though not definitively established, trended higher in trials using higher doses and in men with pre-existing cardiovascular disease [16]. Screening matters.